Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $18.83

Posted by George Bondi on Jun 22nd, 2026

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $18.8333.

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of NeuroPace from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Wells Fargo & Company upgraded shares of NeuroPace to a “strong-buy” rating in a research note on Wednesday, March 18th. HC Wainwright increased their target price on shares of NeuroPace from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research note on Friday, March 27th. Finally, Cantor Fitzgerald raised shares of NeuroPace to a “strong-buy” rating in a research note on Wednesday, March 4th.

Read Our Latest Stock Report on NeuroPace

Institutional Investors Weigh In On NeuroPace

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC grew its stake in shares of NeuroPace by 82.3% in the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after buying an additional 1,110,484 shares in the last quarter. Vanguard Group Inc. grew its position in NeuroPace by 4.9% in the third quarter. Vanguard Group Inc. now owns 1,435,850 shares of the company’s stock worth $14,804,000 after acquiring an additional 66,574 shares in the last quarter. Armistice Capital LLC increased its stake in shares of NeuroPace by 12.6% during the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock worth $13,382,000 after purchasing an additional 145,665 shares during the last quarter. Kotler Kevin acquired a new stake in shares of NeuroPace in the 4th quarter valued at $9,750,000. Finally, Geode Capital Management LLC boosted its holdings in NeuroPace by 6.5% in the fourth quarter. Geode Capital Management LLC now owns 596,248 shares of the company’s stock worth $9,208,000 after purchasing an additional 36,516 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

NeuroPace Stock Performance

Shares of NeuroPace stock opened at $15.63 on Monday. NeuroPace has a 12 month low of $7.56 and a 12 month high of $19.60. The company has a quick ratio of 4.35, a current ratio of 5.38 and a debt-to-equity ratio of 4.08. The stock has a market cap of $532.83 million, a PE ratio of -24.05 and a beta of 1.88. The business has a fifty day simple moving average of $16.22 and a 200-day simple moving average of $15.61.

NeuroPace (NASDAQ:NPCE – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. NeuroPace had a negative return on equity of 108.20% and a negative net margin of 21.67%.The firm had revenue of $22.00 million during the quarter, compared to the consensus estimate of $21.65 million. On average, sell-side analysts anticipate that NeuroPace will post -0.54 EPS for the current fiscal year.

About NeuroPace

(Get Free Report)

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.